



US008853171B2

(12) **United States Patent**
Butler et al.

(10) **Patent No.:** US 8,853,171 B2
(45) **Date of Patent:** Oct. 7, 2014

(54) **1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT**

(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)

(72) Inventors: **Thomas Butler**, Redwood City, CA (US); **Aesop Cho**, Mountain View, CA (US); **Choung U. Kim**, San Carlos, CA (US); **Jay P. Parrish**, Redwood City, CA (US); **Oliver L. Saunders**, San Mateo, CA (US); **Lijun Zhang**, Los Altos Hills, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/649,511**

(22) Filed: **Oct. 11, 2012**

(65) **Prior Publication Data**

US 2013/0034521 A1 Feb. 7, 2013
US 2013/0344028 A2 Dec. 26, 2013

Related U.S. Application Data

(63) Continuation of application No. 13/196,117, filed on Aug. 2, 2011, now Pat. No. 8,318,682, which is a continuation of application No. 12/428,176, filed on Apr. 22, 2009, now Pat. No. 8,008,264.

(60) Provisional application No. 61/047,263, filed on Apr. 23, 2008, provisional application No. 61/139,449, filed on Dec. 19, 2008.

(51) **Int. Cl.**

A01N 43/04 (2006.01)
A61K 31/70 (2006.01)
C07H 5/04 (2006.01)
C07H 7/06 (2006.01)
C07H 19/23 (2006.01)
C07D 487/04 (2006.01)

(52) **U.S. Cl.**

CPC **C07H 19/23** (2013.01); **C07D 487/04** (2013.01)

USPC **514/23**; 536/18.7; 536/29.2; 536/55

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,816,570 A 3/1989 Farquhar
4,968,788 A 11/1990 Farquhar
5,663,159 A 9/1997 Starrett, Jr. et al.
5,792,756 A 8/1998 Starrett, Jr. et al.
6,312,662 B1 11/2001 Erion et al.
6,476,030 B1 11/2002 Carling et al.
6,656,915 B1 12/2003 Bantia et al.

6,909,011 B2 6/2005 Skranc et al.
7,105,493 B2 9/2006 Sommadossi et al.
7,176,203 B2 2/2007 Chambers et al.
7,268,119 B2 9/2007 Cook et al.
7,285,658 B2 10/2007 Cook et al.
7,368,437 B1 5/2008 Bojack et al.
7,429,571 B2 9/2008 Chand et al.
7,514,410 B2 4/2009 Babu et al.
7,560,434 B2 7/2009 Babu et al.
7,598,230 B2 10/2009 Cook et al.
7,608,597 B2 10/2009 Sommadossi et al.
7,713,941 B2 5/2010 Cook et al.
7,807,653 B2 10/2010 Cook et al.
7,842,672 B2 11/2010 Boojamra et al.
7,973,013 B2* 7/2011 Cho et al. 514/23
7,994,139 B2 8/2011 Babu et al.
8,008,264 B2* 8/2011 Butler et al. 514/23
8,012,941 B2 9/2011 Cho et al.
8,012,942 B2 9/2011 Butler et al.
8,071,568 B2 12/2011 Narjes et al.
8,119,607 B2 2/2012 Francom et al.
8,242,085 B2 8/2012 Babu et al.
8,318,682 B2* 11/2012 Butler et al. 514/23
8,415,308 B2 4/2013 Cho et al.
8,455,451 B2 6/2013 Cho et al.
2003/0050229 A1 3/2003 Sommadossi et al.
2004/0006002 A1 1/2004 Sommadossi et al.
2004/0023901 A1 2/2004 Cook et al.
2004/0063658 A1 4/2004 Roberts et al.
2004/0067901 A1 4/2004 Bhat et al.
2004/0138170 A1 7/2004 Montgomery et al.
2005/0187180 A1 8/2005 Loeb et al.
2005/0215513 A1 9/2005 Boojamra et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2367921 C 9/2000
CN 1498221 A 5/2004

(Continued)

OTHER PUBLICATIONS

Arimilli, MN et al. (1997) "Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs", *Antiviral Chemistry & Chemotherapy*, vol. 8(6), p. 557-564.

Benzaria, S. et al. (1996) "Synthesis in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEAs Prodrugs with Improved Oral Bioavailability", *Journal of Medicinal Chemistry*, vol. 39, pp. 4958-4965.

Bio, M. et al. (2004), "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor", *Journal of Organic Chemistry*, vol. 69, pp. 6257-6266.

(Continued)

Primary Examiner — Travis C McIntosh, III

(57) **ABSTRACT**

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

18 Claims, No Drawings